This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Apr 2023


Recently, global experts in AR gathered to find areas of consensus on AR classification and treatment.1 According to the experts, the visual analogue scale (VAS) was the most reliable scale for classification – beating Allergic Rhinitis and its Impact on Asthma (ARIA) classification and categorisation based on own clinical judgement, and taking less than 2 minutes to classify patients’ severity.1 Dr Williams is joined by Dr Jumy Fadugba, the head of Allergy at Penn, and Dr Tiffany Dharia to discuss allergic rhinitis and how it is best managed in primary care. This podcast from the University of Pennsylvania covers diagnosing allergic vs non-allergic rhinitis, the treatment of AR and the efficacy and safety of INCS.1 The experts also found that AR treatment could be further simplified, allowing a patient switching from oral antihistamines (OAH) to intranasal corticosteroids (INCS) to remain on the treatment for 1 months without interim review given that the patient remains controlled.1


  1. Larenas-Linnemann D, et al. Expert consensus using the modified Delphi technique on tools for allergic rhinitis severity classification and treatment options in day-to-day clinical practice. Poster presented at: European Academy of Allergy and Clinical Immunology (EACCI) Hybrid Congress; 2022, Jul 1–3; Prague, Czech Republic and Online (Poster no: 001251)

To report an Adverse Event, please contact the toll free line 0800 CALL GSK (0800 2255 475) or send an email